$47.27
-0.24 (-0.51%)
Open$47.55
Previous Close$47.51
Day High$48.00
Day Low$46.55
52W High$240.00
52W Low$7.26
Volume—
Avg Volume113.5K
Market Cap140.02M
P/E Ratio—
EPS$-38.31
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-5.2% upside
Current
$47.27
$47.27
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.25M | 53.02M | 47.19M |
| Net Income | -110,695,812 | 1.91M | 1.39M |
| Profit Margin | -1,079.9% | 3.6% | 2.9% |
| EBITDA | -109,958,977 | 2.67M | 2.51M |
| Free Cash Flow | — | 1.24M | 802.3K |
| Rev Growth | — | +15.8% | -2.9% |
| Debt/Equity | 0.06 | 0.46 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |